In recent years, biologic therapies have revolutionized the therapeutic approach to rheumatoid arthritis (RA) by specifically targeting molecules involved in the inflammatory process, thereby improving clinical control and slowing the progression of joint damage. This study aims to evaluate the quality of life in patients with rheumatoid arthritis undergoing biologic therapy through a systematic review. This systematic review was conducted in accordance with PRISMA guidelines, supported by Rayyan software to ensure methodological rigor and integrity in study selection and evidence synthesis. A total of eight studies were included in this systematic review, encompassing a cumulative population of 7888 patients diagnosed with RA and treated with biologic therapy. The findings reveal that while there is a general trend toward improved disease control, this improvement does not always translate into a proportional increase in patients’ perceived quality of life, highlighting a dissociation between these two clinical indicators. This discrepancy is influenced by factors such as comorbidities, socioeconomic status, and barriers to treatment accessibility. Biologic therapy represents a significant advancement in the treatment of rheumatoid arthritis, enhancing patients’ quality of life. However, further research is needed to optimize its use and overcome barriers related to accessibility and effectiveness in some instances.